Navigation Links
Scientists Unveil Mechanism Behind Resistance to Severe Malaria

Scientists have discovered why some people are less prone to malaria//. The people with a specific type of hemoglobin — the oxygen-carrying molecule that gives red blood cells their color — are less prone to severe malaria. In a series of experiments, the researchers determined how hemoglobin type C impairs the ability of malaria parasites to cause disease symptoms.

“This research gives us a new insight into malaria, a major global killer that preys especially on young children and claims a life every 30 seconds,” notes Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, where the research was conducted.

“If we better understand the natural protective mechanisms against malaria, we might be able to mimic that protective effect through vaccines or drugs,” says NIAID researcher Thomas E. Wellems, M.D., Ph.D., whose team’s findings appear this week in the journal Nature.

Nature has probably mutated the hemoglobin gene to protect the people from malaria in endemic regions. Hemoglobin exists in several varieties. Hemoglobin A is the most common, but in parts of West Africa, where malaria is rife, one-fourth of the population has at least one gene for hemoglobin C. Children with at least one hemoglobin C gene are less prone to deadly cerebral malaria, in which parasite-infected red blood cells accumulate in the brain. But the mystery is how does hemoglobin C confers this protection to the person. To solve the mystery, Dr. Wellems and his colleagues studied laboratory-infected red blood cells and blood drawn from children with malaria from the African nation of Mali and studied three phenenomenon and found how well parasitized red blood cells can be made to stick to one another, to uninfected red blood cells and to blood vessel walls. These phenomena — known respectively as agglutination, rosetting and cytoadherence — all depend on a parasite p rotein called PfEMP-1.

To evade the immune system, the malarial parasites produce proteins, including PfEMP-1, that remodel the red blood cell’s surface to their advantage. For example, when spikes of PfEMP-1 are distributed evenly over the surface of an infected AA red blood cell, they act like grappling hooks, allowing the parasitized cells to stick in tiny capillaries and avoid being cleared from the bloodstream. When parasite-infected red blood cells stick to blood vessel walls, the resulting inflammation may increase the severity of malarial symptoms, explains Dr. Wellems.

Dr. Wellems and his colleagues found uneven and reduced distribution of PfEMP-1 on the surface of parasite-infected red blood cells from children with at least one hemoglobin C gene. This abnormal distribution of PfEMP-1 significantly impairs the infected cells’ “stickiness.” For instance, laboratory-grown, parasitized AC blood cells agglutinated at a 75 percent lower rate than did AA red blood cells, while parasitized CC blood cells did not stick to each other at all. Rosette formation, in which parasitized cells attach to non-parasitized cells, also occurred significantly less often with AC and CC blood cells than with AA blood cells. Rosettes can impede blood flow in small vessels of the brain, contributing to cerebral malaria and death, notes Dr. Wellems. The scientists showed that AA cells often stick to blood vessel walls, whereas this occurs much less often with both AC and CC blood cells.

Together, the data from Dr. Wellems’ team may explain why red blood cells containing hemoglobin C are less hospitable to malaria parasites than normal AA red blood cells. For people with at least one gene for hemoglobin C, the result is less severe malaria.

Reference: RM Fairhurst et al. Abnormal PfEMP-1 display on hemoglobin C erythrocytes may protect against malaria. Nature 435:1117-21 (2005) doi:10.1038nature/03631. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.naid.nih.gov,
'"/>




Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. Scientists found ancient Human Germ Killer
3. Scientists locate key hormone involved in appetite control
4. Scientists open the book of life
5. Scientists review SARS
6. Scientists crack dengue fever puzzle
7. Scientists push to lower hidden sodium in food
8. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
9. Scientists have found effective brain regions for deep brain stimulation for Parkinson’s
10. Scientists reveal the secrets of sarcasm
11. Scientists Warn Against Food Borne Illnesses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever ... stuff. The season for grass pollen runs from May to July each year; with the ... victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against ...
(Date:3/29/2017)... ... 29, 2017 , ... Wells Pharmacy Network, a proud A4M ... upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO ... leader in the training of physicians, scientists, and members of the public on ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Dr. Angela Cotey, ... orthodontic treatment and accepting new pediatric patients, with or without a referral. Dr. Cotey ... have a better orthodontic outcome and experience. When patients receive early treatment, they may ...
(Date:3/29/2017)... ... March 29, 2017 , ... An ... braces. "The rubber bands used in conjunction with my braces always rubbed against ... design a way to prevent this problem." The O.B.S. was the result of ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... South Hills of Pittsburgh now have easier access to the robotic-assisted total-hip ... Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... 30, 2017  Akcea Therapeutics, a subsidiary of Ionis ... a Phase 2b dose-ranging study of AKCEA-APO(a)-L Rx ... goal of the study is to determine the dose ... in a planned Phase 3 cardiovascular outcome study. ... strategic collaboration with Novartis to develop and commercialize drugs ...
(Date:3/29/2017)... March 29, 2017  Bodycad announced today that ... (FDA) 510(k) clearance for its Bodycad Unicompartmental Knee ... personalized orthopaedic restoration. Bodycad is the first Canadian ... reconstruction implant system. Bodycad,s revolutionary ... restoration of the patient,s unique anatomical features and ...
(Date:3/29/2017)... , March 29, 2017 Avelas Biosciences, Inc., a ... diagnosis through treatment, today announced that Carmine N. Stengone , ... company at the Needham & Company 16 th Annual Healthcare ... a.m. PDT) at the Westin Grand Central Hotel in ... ...
Breaking Medicine Technology: